Sena Nur
Sena Nur has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Sena Nur Başaran
Department of Medical Microbiology, Faculty of Medicine, Ağrı İbrahim Çeçen University, Ağrı, Turkey.
2 shared publicationsLütfiye
1 shared publication- Lütfiye Öksüz
Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University
1 shared publication
Latest Publications
- 10 October 2025
- Published by Springer Nature in International Microbiology
- Vol. 28 (8) , 2821-2828
Postbiotic activity of Akkermansia muciniphila supernatant against antibiotic-resistant Enterococcus faecalis
This study was conducted in response to the growing need for alternative microbial control strategies in the face of escalating antibiotic resistance, aiming to evaluate the antibacterial and antibiofilm potential of postbiotic components derived from Akkermansia muciniphila. Focusing on Enterococcus faecalis, a Gram-positive, biofilm-forming opportunistic pathogen, the effects of cell-free supernatant were analyzed in vitro on both planktonic growth and biofilm structures. The supernatant significantly suppressed planktonic proliferation, while biofilm assays revealed over 50% inhibition of biofilm formation and up to 40% disruption of preformed biofilms. These effects, confirmed via crystal violet staining, indicate that the supernatant possesses both preventive and curative antibiofilm properties. While the immunomodulatory and barrier-enhancing roles of A. muciniphila have been increasingly documented in the literature, this study provides direct experimental evidence of its antibiofilm efficacy, offering a novel perspective on its therapeutic scope. The findings suggest that postbiotics from A. muciniphila act not only through inhibition of bacterial growth but also by targeting biofilm-associated resistance mechanisms. Thus, A. muciniphila supernatant emerges as a promising and innovative candidate for next-generation antimicrobial and antibiofilm strategies, particularly for managing infections involving drug-resistant biofilm-forming pathogens.
- 10 October 2025
- Published by Springer Nature in International Microbiology
- Vol. 28 (8) , 2821-2828
Postbiotic activity of Akkermansia muciniphila supernatant against antibiotic-resistant Enterococcus faecalis
This study was conducted in response to the growing need for alternative microbial control strategies in the face of escalating antibiotic resistance, aiming to evaluate the antibacterial and antibiofilm potential of postbiotic components derived from Akkermansia muciniphila. Focusing on Enterococcus faecalis, a Gram-positive, biofilm-forming opportunistic pathogen, the effects of cell-free supernatant were analyzed in vitro on both planktonic growth and biofilm structures. The supernatant significantly suppressed planktonic proliferation, while biofilm assays revealed over 50% inhibition of biofilm formation and up to 40% disruption of preformed biofilms. These effects, confirmed via crystal violet staining, indicate that the supernatant possesses both preventive and curative antibiofilm properties. While the immunomodulatory and barrier-enhancing roles of A. muciniphila have been increasingly documented in the literature, this study provides direct experimental evidence of its antibiofilm efficacy, offering a novel perspective on its therapeutic scope. The findings suggest that postbiotics from A. muciniphila act not only through inhibition of bacterial growth but also by targeting biofilm-associated resistance mechanisms. Thus, A. muciniphila supernatant emerges as a promising and innovative candidate for next-generation antimicrobial and antibiofilm strategies, particularly for managing infections involving drug-resistant biofilm-forming pathogens.
- 2 April 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (5) , 1-35
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms
Antimicrobial resistance stands as one of the most urgent global health concerns in the twenty-first century, with projections suggesting that deaths related to drug-resistant infections could escalate to 10 million by 2050 if proactive measures are not implemented. In intensive care settings, managing infections caused by multidrug-resistant (MDR) Gram-negative bacteria is particularly challenging, posing a significant threat to public health and contributing substantially to both morbidity and mortality. There are numerous studies on the antibiotics responsible for resistance in Gram-negative bacteria, but comprehensive research on resistance mechanisms against new antibiotics is rare. Considering the possibility that antibiotics may no longer be effective in combating diseases, it is crucial to comprehend the problem of emerging resistance to newly developed antibiotics and to implement preventive measures to curb the spread of resistance. Mutations in porins and efflux pumps play a crucial role in antibiotic resistance by altering drug permeability and active efflux. Porin modifications reduce the influx of antibiotics, whereas overexpression of efflux pumps, particularly those in the resistance-nodulation-cell division (RND) family, actively expels antibiotics from bacterial cells, significantly lowering intracellular drug concentrations and leading to treatment failure. This review examines the mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic characteristics of newly developed antibiotics designed to combat infections caused by MDR and carbapenem-resistant Gram-negative pathogens. The antibiotics discussed include ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, meropenem-vaborbactam, aztreonam-avibactam, delafloxacin, temocillin, plazomicin, cefiderocol, and eravacycline.
- 2 April 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (5) , 1-35
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms
Antimicrobial resistance stands as one of the most urgent global health concerns in the twenty-first century, with projections suggesting that deaths related to drug-resistant infections could escalate to 10 million by 2050 if proactive measures are not implemented. In intensive care settings, managing infections caused by multidrug-resistant (MDR) Gram-negative bacteria is particularly challenging, posing a significant threat to public health and contributing substantially to both morbidity and mortality. There are numerous studies on the antibiotics responsible for resistance in Gram-negative bacteria, but comprehensive research on resistance mechanisms against new antibiotics is rare. Considering the possibility that antibiotics may no longer be effective in combating diseases, it is crucial to comprehend the problem of emerging resistance to newly developed antibiotics and to implement preventive measures to curb the spread of resistance. Mutations in porins and efflux pumps play a crucial role in antibiotic resistance by altering drug permeability and active efflux. Porin modifications reduce the influx of antibiotics, whereas overexpression of efflux pumps, particularly those in the resistance-nodulation-cell division (RND) family, actively expels antibiotics from bacterial cells, significantly lowering intracellular drug concentrations and leading to treatment failure. This review examines the mechanisms of action, resistance profiles, and pharmacokinetic/pharmacodynamic characteristics of newly developed antibiotics designed to combat infections caused by MDR and carbapenem-resistant Gram-negative pathogens. The antibiotics discussed include ceftazidime-avibactam, imipenem-relebactam, ceftolozane-tazobactam, meropenem-vaborbactam, aztreonam-avibactam, delafloxacin, temocillin, plazomicin, cefiderocol, and eravacycline.